The global breast cancer screening tests market was valued at US$ 1.9 Billion in 2022 and is expected to reach US$ 4.4 Billion by 2033. The imaging tests segment with around 54.3% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 7.8% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.9 Billion |
| Market Value 2023 | US$ 2.1 Billion |
| Market Value 2033 | US$ 4.4 Billion |
| CAGR 2023 to 2033 | 7.8% |
| Market Share of Top 5 Countries | 54.5% |
| Key Market Players | AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc, and Siemens Healthineers, Hologic Inc. |
Diagnostic tests are critical in giving accurate care to patients. More precise breast imaging technologies have been developed over the last decades, which has helped to minimise the disease burden of breast cancer.
Since breast cancer is one of the most common cancers in women, the development of various breast cancer awareness programmes has been critical, and many agencies, including the FDA, have launched breast cancer awareness programmes such as the Pink Ribbon Sunday Mammography Awareness Program.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for breast cancer screening tests was around 1.0% of the overall US$ 191.0 Billion of the global cancer diagnostics market in 2022.
Growing demand for technologically sophisticated testing kits and instruments that may improve accuracy, speed, and cost-effectiveness for diagnosis is expected to be the most important growth factor over the projection period.
Rising reimbursement and insurance coverage are likely to further boost testing adoption. Government bodies across various countries have approved certain tests for nationwide reimbursement. This has led to an increase in number of tests being performed either at point-of-care testing site or at the convenience of home.
Patient advocacy organisations and organisations dedicated to breast cancer awareness and assistance are critical in boosting demand for screening tests. These organisations educate and empower women, advocate for the necessity of screening, and work to improve access to screening services.
Breast cancer screening test reimbursement policies and insurance coverage are thus, critical in driving market growth. Beneficial reimbursement policies make screening tests more accessible and inexpensive to patients, resulting in greater utilisation and demand.
Women are becoming more aware of the importance of breast health and regular screenings. Patients are increasingly taking an active role in their own health management, including seeking screening tests. These factors produces an opportune environment for the expansion of the breast cancer screening tests market.
Owed to the above factors, the global market is projected to grow at CAGR of 7.8% in forecasted period.
Breast cancer is one of the most common cancers among women around the world.
Early diagnosis using screening tests is critical for improving treatment outcomes and lowering mortality rates. As a result of the rising incidence and prevalence of breast cancer, the demand for screening tests is increasing.
Worldwide initiatives and awareness campaigns to encourage breast cancer screening have been established by governments and healthcare organizations.
These programs seek to inform the public about the value of early detection and motivate women to have routine screenings. Increased screening rates are a result of government funding and awareness programs, which further fuel the market.
Genetic testing for breast cancer susceptibility, such as BRCA gene testing, has gained prominence. Advances in genetic testing technologies and increased understanding of the genetic factors contributing to breast cancer risk have expanded the scope of screening. Genetic testing drives the adoption of personalized screening approaches and fuels market growth.
Principal Consultant
Breast cancer screening procedures, particularly mammography, can occasionally produce false-positive results, necessitating extra testing, biopsies, and concern for patients. Over diagnosis, or the detection and treatment of tumours that may or may not have caused harm, is also a source of worry. False positives and over diagnosis can increase healthcare expenses and endanger patients.
The most commonly used screening technique, mammography, may have limits in detecting breast cancer in individuals with dense breast tissue. Dense breasts have more fibrous and glandular tissue, making it difficult to detect minor abnormalities. Because of this limitation, women with dense breasts may have missed or delayed diagnoses, necessitating the adoption of additional screening procedures.
The cost of breast cancer screening tests, particularly more advanced imaging methods like breast MRI and molecular breast imaging, can be prohibitively expensive for certain people. Screening test costs and availability can vary depending on healthcare systems, insurance coverage, and individual financial circumstances. High costs may deter people from getting recommended screenings.
The USA occupies 31.4% of market share in 2022 globally. The expansion of the breast cancer screening tests market in the United States is highly impacted by a variety of variables, including public awareness initiatives, government policies, and technological advancements.
The United States Preventive Services Task Force (USPSTF) announced new drafting guidelines for breast cancer screening in May 2023, which significantly reduced the age at which women should begin screening from 50 to 40 years old. The main advantage of screening is that it allows for earlier detection of breast cancer. Breast cancer is virtually 100 percent treatable when detected early. The USPSTF emphasised the importance of greater research regarding screening inequalities across different racial groups in the United States, as well as the benefits of breast ultrasonography and MRI for women with thick breasts.
The goal of these initiatives is to promote regular breast cancer screening, improve early detection rates, and ultimately reduce breast cancer mortality rates.
China expenditure on breast cancer screening test in 2022 was US$ 122.4 Million.
The growing middle-class population in China has largely contributed to the expansion of the breast cancer screening tests market. Breast cancer screening tests are anticipated to become more popular as more individuals obtain access to healthcare facilities.
More importantly, advances in medical technology and the availability of novel screening techniques have supported market expansion. Digital mammography, breast ultrasonography, and breast magnetic resonance imaging (MRI), for example, are becoming more popular in China for breast cancer screening and diagnosis.
In 2022, the Germany held a significant share in the global market and contributed around US$ 132.3 Million. Breast cancer is a major public health concern worldwide, especially in Germany.
Breast cancer screening programmes are in existence in Germany, like in other industrialised nations, to diagnose breast cancer at an early stage. For example, in May 2023, ESMO Breast Cancer conference was held in Germany for breast cancer researchers and physicians with a focus on innovation and care. This campaign was primarily concerned with current advancements in innovative breast cancer diagnostics, biomarkers, and treatments.
These programs usually include mammography screening for women of specific ages.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By diagnostic test type, imaging tests held 54.3% market share in world in 2022.
Imaging tests are the most effective technique to detect breast cancer early, when it is easier to treat and before it has grown large enough to produce symptoms. Regular imaging tests, such as mammograms, can help to reduce the chance of dying from breast cancer. A mammography is currently the most extensively used tool for detecting breast cancer in most women of screening age. These considerations are increasing the use of imaging testing.
The hospitals have a considerable presence in the breast cancer screening tests market, accounting for 42.3% value share in 2022, and exhibiting a high CAGR of 7.1% over the forecast period. The development of improved screening tests for cancer diagnosis and the rise in annual patient visits to hospitals around the world are both contributing factors to the rising usage of genetic testing. Increasing government initiatives to equip hospitals with cutting-edge technology are some of the reasons that are fuelling the growth of this market.
Collaborations and partnerships among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten breast cancer screening test. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of breast cancer screening test. Among the well-known players in this field are:
Similarly, recent developments related to the company’s manufacturing the breast cancer screening test kits have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Diagnostic Test Type, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is valued at US$ 2.1 billion in 2023.
GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corporation, and Hologic Inc. are key breast cancer screening test market players.
Mammography is the key segment by product type and is likely to remain preferred through 2033.
Players opt for product launches, partnerships, and mergers and acquisitions.
China, India, and Japan dominate the Asian market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Product Adoption / Usage Analysis 4.2. Product Features/ USPs 4.3. Breast Cancer Disease Epidemiology 4.4. Reimbursement Scenario 4.5. Regulatory Landscape 4.6. PESTEL Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. Global Life Expectancy Outlook 5.1.3. Global Cancer Diagnostics Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Key Player’s Historic Growth 5.2.2. Increasing prevalence of Cancer 5.2.3. Growing Awareness and Adoption of Breast Cancer Screening Tests 5.2.4. Treatment Seeking Population 5.2.5. Growing Product Approvals 5.2.6. Rising Number of Diagnostic Centres 5.2.7. Research and Development Expenditure by Key Players 5.3. Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Diagnostic Test Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis By Diagnostic Test Type, 2017 to 2022 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Diagnostic Test Type, 2023 to 2033 7.3.1. Blood Marker Tests 7.3.2. Imaging Test Primary Cell-based Therapeutics 7.3.2.1. Mammography 7.3.2.2. MRI screening test 7.3.2.3. Molecular Breast Imaging Test 7.3.2.4. PET scan 7.3.2.5. Ultrasound 7.3.3. Genetic Test 7.3.3.1. Fluorescence In Situ Hybridization 7.3.3.2. HER gene test 7.3.4. Immunohistochemistry Test 7.4. Market Attractiveness Analysis By Diagnostic Test Type 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 8.3.1. Hospitals 8.3.2. Diagnostic Centres 8.3.3. Cancer Institutes 8.3.4. Research Laboratories 8.4. Market Attractiveness Analysis By End User 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 9.1. Introduction 9.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East and Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 10.1. Introduction 10.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 10.3.1. By Country 10.3.1.1. U.S. 10.3.1.2. Canada 10.3.2. By Diagnostic Test Type 10.3.3. By End User 10.4. Market Attractiveness Analysis 10.4.1. By Country 10.4.2. By Diagnostic Test Type 10.4.3. By End User 10.5. Country Level Analysis & Forecast 10.5.1. U.S. Market Analysis 10.5.1.1. .Introduction 10.5.1.2. Market Analysis and Forecast by Market Taxonomy 10.5.1.2.1. By Diagnostic Test Type 10.5.1.2.2. By End User 10.5.2. Canada Market Analysis 10.5.2.1. Introduction 10.5.2.2. Market Analysis and Forecast by Market Taxonomy 10.5.2.2.1. By Diagnostic Test Type 10.5.2.2.2. By End User 10.6. Market Trends 10.7. Key Market Participants - Intensity Mapping 10.8. Drivers and Restraints - Impact Analysis 11. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 11.3.1. By Country 11.3.1.1. Brazil 11.3.1.2. Mexico 11.3.1.3. Argentina 11.3.1.4. Rest of Latin America 11.3.2. By Diagnostic Test Type 11.3.3. By End User 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Diagnostic Test Type 11.4.3. By End User 11.5. Country Level Analysis & Forecast 11.5.1. Brazil Market Analysis 11.5.1.1. .Introduction 11.5.1.2. Market Analysis and Forecast by Market Taxonomy 11.5.1.2.1. By Diagnostic Test Type 11.5.1.2.2. By End User 11.5.2. Mexico Market Analysis 11.5.2.1. Introduction 11.5.2.2. Market Analysis and Forecast by Market Taxonomy 11.5.2.2.1. By Diagnostic Test Type 11.5.2.2.2. By End User 11.5.3. Argentina Market Analysis 11.5.3.1. Introduction 11.5.3.2. Market Analysis and Forecast by Market Taxonomy 11.5.3.2.1. By Diagnostic Test Type 11.5.3.2.2. By End User 11.6. Market Trends 11.7. Key Market Participants - Intensity Mapping 11.8. Drivers and Restraints - Impact Analysis 12. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. Germany 12.3.1.2. France 12.3.1.3. Italy 12.3.1.4. U.K. 12.3.1.5. Spain 12.3.1.6. Russia 12.3.1.7. BENELUX 12.3.1.8. Rest of Europe 12.3.2. By Diagnostic Test Type 12.3.3. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Diagnostic Test Type 12.4.3. By End User 12.5. Country Level Analysis & Forecast 12.5.1. Germany Market Analysis 12.5.1.1. .Introduction 12.5.1.2. Market Analysis and Forecast by Market Taxonomy 12.5.1.2.1. By Diagnostic Test Type 12.5.1.2.2. By End User 12.5.2. France Market Analysis 12.5.2.1. Introduction 12.5.2.2. Market Analysis and Forecast by Market Taxonomy 12.5.2.2.1. By Diagnostic Test Type 12.5.2.2.2. By End User 12.5.3. Italy Market Analysis 12.5.3.1. Introduction 12.5.3.2. Market Analysis and Forecast by Market Taxonomy 12.5.3.2.1. By Diagnostic Test Type 12.5.3.2.2. By End User 12.5.4. U.K. Market Analysis 12.5.4.1. .Introduction 12.5.4.2. Market Analysis and Forecast by Market Taxonomy 12.5.4.2.1. By Diagnostic Test Type 12.5.4.2.2. By End User 12.5.5. Spain Market Analysis 12.5.5.1. .Introduction 12.5.5.2. Market Analysis and Forecast by Market Taxonomy 12.5.5.2.1. By Diagnostic Test Type 12.5.5.2.2. By End User 12.5.6. Russia Market Analysis 12.5.6.1. .Introduction 12.5.6.2. Market Analysis and Forecast by Market Taxonomy 12.5.6.2.1. By Diagnostic Test Type 12.5.6.2.2. By End User 12.5.7. BENELUX Market Analysis 12.5.7.1. .Introduction 12.5.7.2. Market Analysis and Forecast by Market Taxonomy 12.5.7.2.1. By Diagnostic Test Type 12.5.7.2.2. By End User 12.6. Market Trends 12.7. Key Market Participants - Intensity Mapping 12.8. Drivers and Restraints - Impact Analysis 13. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. India 13.3.1.2. Thailand 13.3.1.3. Indonesia 13.3.1.4. Malaysia 13.3.1.5. Rest of South Asia 13.3.2. By Diagnostic Test Type 13.3.3. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Diagnostic Test Type 13.4.3. By End User 13.5. Country Level Analysis & Forecast 13.5.1. India Market Analysis 13.5.1.1. .Introduction 13.5.1.2. Market Analysis and Forecast by Market Taxonomy 13.5.1.2.1. By Diagnostic Test Type 13.5.1.2.2. By End User 13.5.2. Thailand Market Analysis 13.5.2.1. .Introduction 13.5.2.2. Market Analysis and Forecast by Market Taxonomy 13.5.2.2.1. By Diagnostic Test Type 13.5.2.2.2. By End User 13.5.3. Indonesia Market Analysis 13.5.3.1. Introduction 13.5.3.2. Market Analysis and Forecast by Market Taxonomy 13.5.3.2.1. By Diagnostic Test Type 13.5.3.2.2. By End User 13.5.4. Malaysia Market Analysis 13.5.4.1. Introduction 13.5.4.2. Market Analysis and Forecast by Market Taxonomy 13.5.4.2.1. By Diagnostic Test Type 13.5.4.2.2. By End User 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 14. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Diagnostic Test Type 14.3.3. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Diagnostic Test Type 14.4.3. By End User 14.5. Country Level Analysis & Forecast 14.5.1. China Market Analysis 14.5.1.1. .Introduction 14.5.1.2. Market Analysis and Forecast by Market Taxonomy 14.5.1.2.1. By Diagnostic Test Type 14.5.1.2.2. By End User 14.5.2. Japan Market Analysis 14.5.2.1. Introduction 14.5.2.2. Market Analysis and Forecast by Market Taxonomy 14.5.2.2.1. By Diagnostic Test Type 14.5.2.2.2. By End User 14.5.3. South Korea Market Analysis 14.5.3.1. Introduction 14.5.3.2. Market Analysis and Forecast by Market Taxonomy 14.5.3.2.1. By Diagnostic Test Type 14.5.3.2.2. By End User 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 15. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Australia 15.3.1.2. New Zealand 15.3.2. By Diagnostic Test Type 15.3.3. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Diagnostic Test Type 15.4.3. By End User 15.5. Country Level Analysis & Forecast 15.5.1. Australia Market Analysis 15.5.1.1. .Introduction 15.5.1.2. Market Analysis and Forecast by Market Taxonomy 15.5.1.2.1. By Diagnostic Test Type 15.5.1.2.2. By End User 15.5.2. New Zealand Market Analysis 15.5.2.1. Introduction 15.5.2.2. Market Analysis and Forecast by Market Taxonomy 15.5.2.2.1. By Diagnostic Test Type 15.5.2.2.2. By End User 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. GCC Countries 16.3.1.2. Türkiye 16.3.1.3. Northern Africa 16.3.1.4. South Africa 16.3.1.5. Rest of Middle East and Africa 16.3.2. By Diagnostic Test Type 16.3.3. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Diagnostic Test Type 16.4.3. By End User 16.5. Country Level Analysis & Forecast 16.5.1. GCC Countries Market Analysis 16.5.1.1. .Introduction 16.5.1.2. Market Analysis and Forecast by Market Taxonomy 16.5.1.2.1. By Diagnostic Test Type 16.5.1.2.2. By End User 16.5.2. Türkiye Market Analysis 16.5.2.1. Introduction 16.5.2.2. Market Analysis and Forecast by Market Taxonomy 16.5.2.2.1. By Diagnostic Test Type 16.5.2.2.2. By End User 16.5.3. Northern Africa Market Analysis 16.5.3.1. Introduction 16.5.3.2. Market Analysis and Forecast by Market Taxonomy 16.5.3.2.1. By Diagnostic Test Type 16.5.3.2.2. By End User 16.5.4. South Africa Market Analysis 16.5.4.1. Introduction 16.5.4.2. Market Analysis and Forecast by Market Taxonomy 16.5.4.2.1. By Diagnostic Test Type 16.5.4.2.2. By End User 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Share Analysis of Top Players 17.3. Market Presence Analysis 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive 18.3.1. AstraZeneca 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Key Financials 18.3.1.4. Sales Footprint 18.3.1.5. SWOT Analysis 18.3.1.6. Strategy Overview 18.3.1.6.1. Marketing Strategy 18.3.1.6.2. Product Strategy 18.3.1.6.3. Channel Strategy 18.3.2. Novartis 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Key Financials 18.3.2.4. Sales Footprint 18.3.2.5. SWOT Analysis 18.3.2.6. Strategy Overview 18.3.2.6.1. Marketing Strategy 18.3.2.6.2. Product Strategy 18.3.2.6.3. Channel Strategy 18.3.3. Sanofi 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Key Financials 18.3.3.4. Sales Footprint 18.3.3.5. SWOT Analysis 18.3.3.6. Strategy Overview 18.3.3.6.1. Marketing Strategy 18.3.3.6.2. Product Strategy 18.3.3.6.3. Channel Strategy 18.3.4. Pfizer 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Key Financials 18.3.4.4. Sales Footprint 18.3.4.5. SWOT Analysis 18.3.4.6. Strategy Overview 18.3.4.6.1. Marketing Strategy 18.3.4.6.2. Product Strategy 18.3.4.6.3. Channel Strategy 18.3.5. Bayer AG 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Key Financials 18.3.5.4. Sales Footprint 18.3.5.5. SWOT Analysis 18.3.5.6. Strategy Overview 18.3.5.6.1. Marketing Strategy 18.3.5.6.2. Product Strategy 18.3.5.6.3. Channel Strategy 18.3.6. GlaxoSmithKline plc 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Key Financials 18.3.6.4. Sales Footprint 18.3.6.5. SWOT Analysis 18.3.6.6. Strategy Overview 18.3.6.6.1. Marketing Strategy 18.3.6.6.2. Product Strategy 18.3.6.6.3. Channel Strategy 18.3.7. Siemens Healthineers 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Key Financials 18.3.7.4. Sales Footprint 18.3.7.5. SWOT Analysis 18.3.7.6. Strategy Overview 18.3.7.6.1. Marketing Strategy 18.3.7.6.2. Product Strategy 18.3.7.6.3. Channel Strategy 18.3.8. Hologic Inc. 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Key Financials 18.3.8.4. Sales Footprint 18.3.8.5. SWOT Analysis 18.3.8.6. Strategy Overview 18.3.8.6.1. Marketing Strategy 18.3.8.6.2. Product Strategy 18.3.8.6.3. Channel Strategy 18.3.9. General Electric Company 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Key Financials 18.3.9.4. Sales Footprint 18.3.9.5. SWOT Analysis 18.3.9.6. Strategy Overview 18.3.9.6.1. Marketing Strategy 18.3.9.6.2. Product Strategy 18.3.9.6.3. Channel Strategy 18.3.10. Koninklijke Philips NV 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Key Financials 18.3.10.4. Sales Footprint 18.3.10.5. SWOT Analysis 18.3.10.6. Strategy Overview 18.3.10.6.1. Marketing Strategy 18.3.10.6.2. Product Strategy 18.3.10.6.3. Channel Strategy 18.3.11. Fujifilm Holdings 18.3.11.1. Overview 18.3.11.2. Product Portfolio 18.3.11.3. Key Financials 18.3.11.4. Sales Footprint 18.3.11.5. SWOT Analysis 18.3.11.6. Strategy Overview 18.3.11.6.1. Marketing Strategy 18.3.11.6.2. Product Strategy 18.3.11.6.3. Channel Strategy 18.3.12. A&G Pharmaceutical, Inc. 18.3.12.1. Overview 18.3.12.2. Product Portfolio 18.3.12.3. Key Financials 18.3.12.4. Sales Footprint 18.3.12.5. SWOT Analysis 18.3.12.6. Strategy Overview 18.3.12.6.1. Marketing Strategy 18.3.12.6.2. Product Strategy 18.3.12.6.3. Channel Strategy 18.3.13. Biocrates Life Sciences AG 18.3.13.1. Overview 18.3.13.2. Product Portfolio 18.3.13.3. Key Financials 18.3.13.4. Sales Footprint 18.3.13.5. SWOT Analysis 18.3.13.6. Strategy Overview 18.3.13.6.1. Marketing Strategy 18.3.13.6.2. Product Strategy 18.3.13.6.3. Channel Strategy 18.3.14. Metabolomic Technologies, Inc. 18.3.14.1. Overview 18.3.14.2. Product Portfolio 18.3.14.3. Key Financials 18.3.14.4. Sales Footprint 18.3.14.5. SWOT Analysis 18.3.14.6. Strategy Overview 18.3.14.6.1. Marketing Strategy 18.3.14.6.2. Product Strategy 18.3.14.6.3. Channel Strategy 18.3.15. Myriad Genetics 18.3.15.1. Overview 18.3.15.2. Product Portfolio 18.3.15.3. Key Financials 18.3.15.4. Sales Footprint 18.3.15.5. SWOT Analysis 18.3.15.6. Strategy Overview 18.3.15.6.1. Marketing Strategy 18.3.15.6.2. Product Strategy 18.3.15.6.3. Channel Strategy 18.3.16. OncoCyte Corporation 18.3.16.1. Overview 18.3.16.2. Product Portfolio 18.3.16.3. Key Financials 18.3.16.4. Sales Footprint 18.3.16.5. SWOT Analysis 18.3.16.6. Strategy Overview 18.3.16.6.1. Marketing Strategy 18.3.16.6.2. Product Strategy 18.3.16.6.3. Channel Strategy 18.3.17. POC Medical Systems, Inc. 18.3.17.1. Overview 18.3.17.2. Product Portfolio 18.3.17.3. Key Financials 18.3.17.4. Sales Footprint 18.3.17.5. SWOT Analysis 18.3.17.6. Strategy Overview 18.3.17.6.1. Marketing Strategy 18.3.17.6.2. Product Strategy 18.3.17.6.3. Channel Strategy 18.3.18. Hologic, Inc. 18.3.18.1. Overview 18.3.18.2. Product Portfolio 18.3.18.3. Key Financials 18.3.18.4. Sales Footprint 18.3.18.5. SWOT Analysis 18.3.18.6. Strategy Overview 18.3.18.6.1. Marketing Strategy 18.3.18.6.2. Product Strategy 18.3.18.6.3. Channel Strategy 18.3.19. Provista Diagnostics, Inc. 18.3.19.1. Overview 18.3.19.2. Product Portfolio 18.3.19.3. Key Financials 18.3.19.4. Sales Footprint 18.3.19.5. SWOT Analysis 18.3.19.6. Strategy Overview 18.3.19.6.1. Marketing Strategy 18.3.19.6.2. Product Strategy 18.3.19.6.3. Channel Strategy 18.3.20. BioTime, Inc. 18.3.20.1. Overview 18.3.20.2. Product Portfolio 18.3.20.3. Key Financials 18.3.20.4. Sales Footprint 18.3.20.5. SWOT Analysis 18.3.20.6. Strategy Overview 18.3.20.6.1. Marketing Strategy 18.3.20.6.2. Product Strategy 18.3.20.6.3. Channel Strategy 19. Assumptions and Acronyms Used 20. Research Methodology
Healthcare
December 2023
REP-GB-16943
443 pages
Explore Healthcare Insights
View Reports
Breast Cancer Screening Tests Market
